#ACHV↓

ACHV/ 10/17/2025 · 8:30 AM

FDA Fast-Tracks First Vaping Cessation Treatment for Cytisinicline

Achieve Life Sciences receives FDA's National Priority Voucher for cytisinicline, potentially the first approved treatment to help people quit vaping and e-cigarettes.

ACHV/ 09/03/2025 · 9:03 AM

FDA Reviews Achieve Life Sciences' Cytisinicline for Smoking Cessation

FDA accepted cytisinicline NDA for smoking cessation, with a PDUFA date of June 20, 2026. This marks a significant step, potentially offering the first new FDA-approved therapy in two decades to combat nicotine dependence, supported by strong clinical data and safety.